DESCRIPTION

Hydroxocobalamin injection is a sterile solution of hydroxocobalamin for intramuscular administration. Each mL contains: Hydroxocobalamin Acetate equivalent to 1000 mcg Hydroxocobalamin, Sodium Acetate Anhydrous 0.2 mg, Glacial Acetic Acid 0.442 mg, Sodium Chloride 8.2 mg, with Methylparaben 1.5 mg and Propylparaben 0.2 mg as preservatives, in Water for Injection q.s. Additional Glacial Acetic Acid and/or Sodium Acetate may have been used to adjust pH. pH range is 3.5 to 5.0.

Hydroxocobalamin appears as dark red orthorhombic needles or as an amorphous or crystalline red powder. It is very hygroscopic in the anhydrous form, and moderately soluble in water. It has a molecular weight of 1346.37. The vitamin B<sub>12</sub> coenzymes are very unstable in light. Hydroxocobalamin shares the cobalamin molecular structure with cyanocobalamin.

The chemical name is α-(5,6-dimethylbenzimidazoly) hydroxocobamide. The empirical formula is C<sub>62</sub>H<sub>89</sub>CoN<sub>13</sub>O<sub>15</sub>P and its structural formula is:

![Structural formula of hydroxocobalamin](image)

The cobalt content is 4.34%.

CLINICAL PHARMACOLOGY

Vitamin B<sub>12</sub> is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis.

Fifty percent of the administered dose of hydroxocobalamin disappears from the injection site in 2.5 hours. Hydroxocobalamin is bound to plasma proteins and stored in the liver. It is excreted in the bile and undergoes some enterohepatic recycling. Within 72 hours after injection of 500 to 1000 mcg of hydroxocobalamin, 16 to 66 percent of the injected dose may appear in the urine. The major portion is excreted within the first 24 hours.
INDICATIONS AND USAGE

I. Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. (Isolated vitamin B₁₂ deficiency is very rare).

II. Dietary deficiency of Vitamin B₁₂, occurring in strict vegetarians and in their breast-fed infants.

III. Malabsorption of vitamin B₁₂, resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B₁₂ absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B₁₂ deficiency.

IV. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B₁₂ deficiency. Structural lesions leading to vitamin B₁₂ deficiency include regional ileitis, ileal resections, malignancies, etc.

V. Competition for Vitamin B₁₂ by intestinal parasites or bacteria.

VI. Inadequate utilization of vitamin B₁₂. This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia.

VII. For the Schilling Test.

CONTRAINDICATION

Hypersensitivity to any component of this medication.

WARNINGS

Avoid the intravenous route.

Folic acid is not a substitute for vitamin B₁₂ although it may improve vitamin B₁₂ deficient megaloblastic anemia. Exclusive use of folic acid in treating vitamin B₁₂ deficient megaloblastic anemia could result in progressive and irreversible neurologic damage.

Blunted or impeded therapeutic response to vitamin B₁₂ may be due to such conditions as infection, uremia, drugs having bone marrow suppressant properties such as chloramphenicol, and concurrent iron or folic acid deficiency.

PRECAUTIONS

General

The validity of diagnostic vitamin B₁₂ or folic acid blood assays could be compromised by medications, and this should be considered before relying on such tests for therapy.

Vitamin B₁₂ is not a substitute for folic acid and since it might improve folic acid deficient megaloblastic anemia, indiscriminate use of vitamin B₁₂ could mask the true diagnosis.

Hypokalemia and thrombocytosis could occur upon conversion of severe megaloblastic to normal erythropoiesis with B₁₂ therapy. Therefore, serum potassium levels and the platelet count should be monitored carefully during therapy.

Vitamin B₁₂ deficiency may suppress the signs of polycythemia vera. Treatment with vitamin B₁₂ may
unmask this condition.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

Studies of carcinogenicity, mutagenesis, or impairment of fertility have not been performed with hydroxocobalamin.

**Pregnancy**

Teratogenic Effects: Pregnancy Category C: Animal reproduction studies have not been conducted with hydroxocobalamin. It is also not known whether hydroxocobalamin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hydroxocobalamin should be given to a pregnant woman only if clearly needed.

**ADVERSE REACTIONS**

Mild transient diarrhea, itching, transitory exanthema, feeling of swelling of entire body, and anaphylaxis.

A few patients may experience pain after injection of hydroxocobalamin.

To report SUSPECTED ADVERSE EVENTS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or [http://www.fda.gov/](http://www.fda.gov/) for voluntary reporting of adverse reactions.

**OVERDOSAGE**

The intravenous LD$_{50}$ of hydroxocobalamin in mice is greater than 50 mL/kg.

**DOSAGE AND ADMINISTRATION**

Protect from light.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Hydroxocobalamin injection should be given only intramuscularly.

In patients with Addisonian Pernicious Anemia, parenteral therapy with vitamin B$_{12}$ is the recommended method of treatment and will be required for the remainder of the patient’s life. Oral therapy is not dependable. In other patients with vitamin B$_{12}$ deficiency, the duration of therapy and route of administration will depend upon the cause and whether or not it is reversible.

Confirmatory diagnostic studies should be performed prior to initiating therapy, if possible, and the patient should be followed with appropriate studies to demonstrate hematologic improvement (Hgb, hematocrit, RBC, reticulocyte count). A diagnostic trial utilizing physiologic doses of vitamin B$_{12}$ (1 mcg daily) and observing daily reticulocyte counts after establishing a baseline may also be performed. The observation of reticulocytosis which usually occurs between the third and tenth day of therapy confirms the diagnosis of vitamin B$_{12}$ deficiency.

In seriously ill patients it may be advisable to administer both vitamin B$_{12}$ and folic acid while awaiting the results of distinguishing laboratory studies. It is not necessary to withhold vitamin B$_{12}$ therapy until the precise cause of B$_{12}$ deficiency is established since absorption studies can be performed at any time.

Serum potassium should be closely observed the first 48 hours and potassium should be administered if necessary.

**Treatment of Vitamin B$_{12}$ Deficiency**
Thirty mcg daily for 5 to 10 days followed by 100 to 200 mcg monthly injected intramuscularly. If the patient is critically ill, or has neurologic disease, an infectious disease or hyperthyroidism, considerably higher doses may be indicated. However, current data indicate that the optimum obtainable neurologic response may be expected with a dosage of vitamin B₁₂ sufficient to produce good hematologic response. Children may be given a total of 1 to 5 mg over a period of 2 or more weeks in doses of 100 mcg, then 30 to 50 mcg every 4 weeks for maintenance.

Patients who have normal intestinal absorption may be treated with an oral therapeutic multivitamin preparation, containing 15 mcg vitamin B₁₂ daily.

**Schilling Test**

The flushing dose is 1000 mcg.

**HOW SUPPLIED**

Hydroxocobalamin Injection USP, 1000 mcg/mL is available in a 30 mL multiple dose vial, individually boxed.

Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.] **PROTECT FROM LIGHT.**

Literature revised: January 2017

Manufactured by:

**Hikma Farmaceutica** (Portugal)
S.A. 2705-906 Terrugem SNT, Portugal

Distributed by:

**Actavis Pharma, Inc.**
Parsippany, NJ 07054 USA

**PIN229-WAT/2**

**PRINCIPAL DISPLAY PANEL**

NDC 0591-2888-30
30 mL Sterile Multiple Dose Vial

Hydroxocobalamin
Injection USP

30,000 mcg/30 mL
(1,000 mcg/mL)

**FOR INTRAMUSCULAR USE ONLY**

Actavis
Rx only
HYDROXOCOBALAMIN
hydroxocobalamin injection, solution

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC: 0591-2888</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>INTRAMUSCULAR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROXOCOBALAMIN ACETATE (UNII: S535M27N3Q) (HYDROXOCOBALAMIN - UNII:Q40X8H4220)</td>
<td>HYDROXOCOBALAMIN</td>
<td>1000 ug in 1 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>SODIUM ACETATE ANHYDROUS (UNII: NVG71ZZ7P0)</td>
<td>0.2 mg in 1 mL</td>
</tr>
<tr>
<td>ACETIC ACID (UNII: Q40Q9N063P)</td>
<td>0.442 mg in 1 mL</td>
</tr>
<tr>
<td>SODIUM CHLORIDE (UNII: 451W47Q8X)</td>
<td>8.2 mg in 1 mL</td>
</tr>
<tr>
<td>METHYLPARABEN (UNII: A2I8C7HI9T)</td>
<td>1.5 mg in 1 mL</td>
</tr>
<tr>
<td>PROPYLPARABEN (UNII: Z8IX2SC1OH)</td>
<td>0.2 mg in 1 mL</td>
</tr>
<tr>
<td>WATER (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0591-2888-30</td>
<td>1 in 1 CARTON</td>
<td>11/12/2010</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>30 mL in 1 VIAL, MULTI-DOSE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA085998</td>
<td>11/12/2010</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Actavis Pharma, Inc. (119723554)

Revised: 12/2017